Intellectual Property - January 12, 2024
Capitainer secures three US patents
Capitainer has announced the grant of three US patents for their soon to be launched plasma/serum separation device. “These patents reinforce our strategic position, facilitating Capitainer’s expansion in the US market. The recognition from the United States Patent Office is a testament to the technological advancements we’ve achieved. This enables us to extend our advanced […]
Intellectual Property - September 12, 2023
Elicera Therapeutics receives Notice of Allowance for Chinease patent
Elicera Therapeutics has received a Notice of Allowance from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the patent can be kept in force until 2036. “iTANK is one of our key assets and together with the recently approved European patent we now […]
Intellectual Property - August 23, 2023
BioArctic receives patent in Japan
The Japanese Patent Office (JPO) is granting a new drug substance patent for the antibody BAN0805, invented by BioArctic as a potential treatment of Parkinson’s disease. The patent will expire in 2041, with the possibility of a patent term extension up until 2046. The aim is to develop a treatment that halts or slows the […]
Intellectual Property - August 9, 2023
InDex Pharmaceuticals has been granted a new patent
The company has announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE. The patent will provide an exclusivity period until September 2042, with […]
Business - July 3, 2023
Orexo wins patent litigation in the US
The US District Court for the District of New Jersey ruled in favor of Orexo in its patent litigation against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc. (collectively “Sun”) regarding ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII) in the US. The district court found that […]
Intellectual Property - May 22, 2023
AlzeCure is granted European patent
AlzeCure Pharma has announced that the European Patent Office (EPO) has granted a patent covering the company’s candidate drug ACD856, which is developed against Alzheimer’s disease and other disorders with cognitive impairment. “This is another key step for ACD856, given that we have previously also been granted a US patent for this substance. This further […]
